Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Seres Therapeutics (MCRB) Misses Q1 EPS by 9c
May 4, 2022 7:17 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.61), $0.09 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $1.49 million versus the consensus estimate of $8.48 million.
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
... More